Patients in our study with HR-positive/HER2-negative breast cancers, had a median PFS of 5.6 vs. 2.2 months (p=0.0096) in those treated with IO plus chemotherapy compared to IO monotherapy. The gene discussed is ERBB2; the disease is breast carcinoma.